Table 1 –
Patient and clinical characteristicsa
| N (%) | ||
|---|---|---|
| Patients, n | 551 | |
| Age at SBRT (yr) | Median (IQR; N = 551) | 70 (65–74) |
| Clinical T stage | T1a | 3 (0.5) |
| T1c | 401 (72.8) | |
| T2a | 104 (18.9) | |
| T2b | 34 (6.2) | |
| T2c | 9(1.6) | |
| Initial PSA (ng/ml) | Median (range; N = 551) | 6.4 (0.3–19.6) |
| Gleason score | Group 1 (3 + 3) | 67 (12.2) |
| Group 2 (3 + 4) | 349 (63.3) | |
| Group 3 (4 + 3) | 135 (24.5) | |
| Prostate volume | Median (IQR; N = 529) | 38.0 (28.0–53.0) |
| Prognostic risk group | Low | 53 (9.6) |
| Favorable-intermediate | 226 (41) | |
| Unfavorable-intermediate | 272 (49.4) | |
| ECE | Unknown | 18 (3.3) |
| Negative | 363 (65.9) | |
| Possible | 71 (12.9) | |
| Suspicious | 77 (14) | |
| Positive | 22 (4) | |
| SVI | Unknown | 18 (3.3) |
| Negative | 527 (95.6) | |
| Possible | 1 (0.2) | |
| Suspicious | 2 (0.4) | |
| Positive | 3 (0.5) | |
| Lymphadenopathy | Unknown | 18 (3.3) |
| Negative | 533 (96.7) | |
| % Positive cores | Median (IQR; N = 551) | 0.3 (0.2–0.5) |
| IIEF baseline score | Median (IQR; N = 530) | 9.0 (2.0–25.0) |
| IPSS baseline score | Median (IQR; N = 547) | 6.0 (3.0–11.0) |
ECE = extracapsular extension; IIEF = International Index of Erectile Function; IPSS = International Prostate Symptom Score; IQR = interquartile range; PSA = prostate-specific antigen; SBRT = stereotactic body radiotherapy; SVI = seminal vesicle invasion.
a
Numbers in parentheses represent frequency with percent of total unless otherwise stated.